Home
RLYB

RLYB

Rallybio Corporation

as of 12-05-2025 4:00pm EST

$0.66

$0.02

-3.02%

Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Chart Type:

Time Range:

Founded:	2018	Country:	United States
Employees:	N/A	City:	NEW HAVEN
Market Cap:	24.1M	IPO Year:	2021
Target Price:	N/A	AVG Volume (30 days):	173.4K
Analyst Decision:	Hold	Number of Analysts:	2
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-0.32	EPS Growth:	N/A
52 Week Low/High:	$0.22 - $1.24	Next Earning Date:	11-06-2025
Revenue:	$674,000	Revenue Growth:	12.71%
Revenue Growth (this year):	17.61%	Revenue Growth (next year):	N/A

AI-Powered RLYB Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold

Model Accuracy: 76.87%

76.87%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full RLYB Forecast & Prediction with Hourly Data

Compare RLYB vs Leading Stocks

See how RLYB stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free RLYB Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "RLYB Rallybio Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.